Drug Profile
Lymphokine activated killer cells - Chiron Corporation
Latest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer Chiron Corporation; Nonindustrial source
- Class Immunotherapies; NKT cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Leukaemia; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cancer; Solid tumours; Viral infections
Most Recent Events
- 17 Jan 2019 DC/MoA project: Thes request send to update DC and Moa
- 01 Sep 2000 Clinical trials in Leukaemia in Italy (Infusion)
- 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation